Key Molecular Drivers of Chronic Lymphocytic Leukemia.

[1]  T. Stankovic,et al.  ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. , 2016, Blood.

[2]  M. Larrayoz,et al.  The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 , 2016, Leukemia.

[3]  L. Liotta,et al.  Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands? , 2016, Leukemia.

[4]  M. Hallek,et al.  Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. , 2016, The Lancet. Oncology.

[5]  D. Rossi,et al.  Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia , 2016, Haematologica.

[6]  T. Haferlach,et al.  Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia , 2015 .

[7]  T. Kipps,et al.  Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study , 2015 .

[8]  A. Palumbo,et al.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. , 2015, The New England journal of medicine.

[9]  K. Stamatopoulos,et al.  Prognostic relevance of MYD88 mutations in CLL: the jury is still out. , 2015, Blood.

[10]  H. Pelicano,et al.  Abstract 4560: Targeting chronic lymphocytic leukemia with p53 deficiency with phenethyl isothiocyanate , 2015 .

[11]  A. Wiestner,et al.  Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo , 2015, Clinical Cancer Research.

[12]  Y. Pekarsky,et al.  miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eμ-TCL1 mouse model , 2015, Oncotarget.

[13]  E. Campo,et al.  The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia , 2015, Oncotarget.

[14]  G. Macino,et al.  Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR‐132 and miR‐212 , 2015, Genes, chromosomes & cancer.

[15]  A. Pettitt,et al.  Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia , 2015, Molecular & Cellular Proteomics.

[16]  G. Laurent,et al.  Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients , 2015, European journal of haematology.

[17]  S. Gibson,et al.  ZAP70 expression directly promotes chronic lymphocytic leukaemia cell adhesion to bone marrow stromal cells , 2015, British journal of haematology.

[18]  J. Grimsby,et al.  Integrated Single-Cell Detection of Genotype and Phenotype in SF3B1-Mutated Chronic Lymphocytic Leukemia Cells , 2014 .

[19]  R. Improgo,et al.  Inhibition of the Notch1 Pathway in Chronic Lymphocytic Leukemia Promotes Apoptosis and Inhibits Proliferation , 2014 .

[20]  C. Nabhan,et al.  Chronic lymphocytic leukemia: a clinical review. , 2014, JAMA.

[21]  J. Burger,et al.  Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. , 2014, Pharmacology & therapeutics.

[22]  T. Stankovic,et al.  The impact of SF3B1 mutations in CLL on the DNA-damage response , 2014, Leukemia.

[23]  C. Fegan,et al.  Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition , 2014, Leukemia.

[24]  S. Gibson,et al.  Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling , 2014, Cell Death and Disease.

[25]  Emanuela M. Ghia,et al.  Abstract 343: Targeting SF3B1 mediated splicing control of Mcl-1 in chronic lymphocytic leukemia , 2014 .

[26]  G. Gaidano,et al.  The Role of CD49d in Chronic Lymphocytic Leukaemia: Microenvironmental Interactions and Clinical Relevance , 2014, EMJ Hematology.

[27]  C. Fegan,et al.  Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. , 2014, Journal of proteome research.

[28]  G. Gaidano,et al.  Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. , 2014, Seminars in hematology.

[29]  Y. Pekarsky,et al.  Role of miR-15/16 in CLL , 2014, Cell Death and Differentiation.

[30]  E. Campo,et al.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.

[31]  Z. Estrov,et al.  Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. , 2014, Blood.

[32]  E. Giné,et al.  Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. , 2014, Blood.

[33]  T. Hartmann.  CLL cells under flow. , 2014, Blood.

[34]  C. Fegan,et al.  Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. , 2014, Blood.

[35]  T. Stankovic,et al.  ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial , 2014, Haematologica.

[36]  Stephan Stilgenbauer,et al.  Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Gribben,et al.  The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. , 2014, Seminars in cancer biology.

[38]  Jian-yong Li,et al.  Role of chemokines and their receptors in chronic lymphocytic leukemia , 2014, Cancer biology & therapy.

[39]  J. Philippé,et al.  Expression of ZAP70 in chronic lymphocytic leukaemia activates NF‐κB signalling , 2013, British journal of haematology.

[40]  S. Deaglio,et al.  Multiple metamorphoses of CD38 from prognostic marker to disease modifier to therapeutic target in chronic lymphocytic leukemia. , 2013, Current topics in medicinal chemistry.

[41]  Christian Billard,et al.  Apoptosis inducers in chronic lymphocytic leukemia , 2013, Oncotarget.

[42]  T. Shanafelt,et al.  CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. López-Guillermo,et al.  Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL , 2013 .

[44]  H. Kantarjian,et al.  Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients , 2013 .

[45]  Michael Hallek,et al.  Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment , 2013, American journal of hematology.

[46]  J. Miyazaki,et al.  Functional Analysis of Tcl1 Using Tcl1-Deficient Mouse Embryonic Stem Cells , 2013, PloS one.

[47]  Catherine J. Wu,et al.  SF3B1 mutations in chronic lymphocytic leukemia. , 2013, Blood.

[48]  G. Rabinovich,et al.  Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1 , 2013, Leukemia.

[49]  F. Speleman,et al.  CLL Cells Respond to B-Cell Receptor Stimulation with a MicroRNA/mRNA Signature Associated with MYC Activation and Cell Cycle Progression , 2013, PloS one.

[50]  B. Hock,et al.  Clinical Significance of Plasma Levels of Soluble CD40 in Patients with Chronic Lymphocytic Leukemia , 2013 .

[51]  L. Rassenti,et al.  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44 , 2013, Proceedings of the National Academy of Sciences.

[52]  G. Juliusson,et al.  NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia , 2013, Leukemia.

[53]  D. Catovsky,et al.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.

[54]  C. Croce,et al.  Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. , 2013, Blood.

[55]  M. Dyer,et al.  Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  N. Chiorazzi.  Implications of new prognostic markers in chronic lymphocytic leukemia. , 2012, Hematology. American Society of Hematology. Education Program.

[57]  M. Cazzola,et al.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.

[58]  T. Stankovic,et al.  SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy , 2012 .

[59]  A. Michie,et al.  Dasatinib Inhibits CXCR4 Signaling in Chronic Lymphocytic Leukaemia Cells and Impairs Migration Towards CXCL12 , 2012, PloS one.

[60]  Alfonso Valencia,et al.  Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia , 2012, Nature Genetics.

[61]  R. Foà,et al.  Molecular pathogenesis of chronic lymphocytic leukemia. , 2012, The Journal of clinical investigation.

[62]  W. Wierda.  Making advances in first-line chronic lymphocytic leukemia treatment. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Byrd,et al.  The B-cell receptor signaling pathway as a therapeutic target in CLL. , 2012, Blood.

[64]  V. Gianfelici.  Activation of the NOTCH1 pathway in chronic lymphocytic leukemia , 2012, Haematologica.

[65]  Luca Laurenti,et al.  NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL , 2012, Haematologica.

[66]  M. Davids,et al.  Cell Trafficking in Chronic Lymphocytic Leukemia. , 2012, Open journal of hematology.

[67]  Andrew S Duncombe,et al.  Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. , 2012, Blood.

[68]  Chris Pepper,et al.  Defining the prognosis of early stage chronic lymphocytic leukaemia patients , 2012, British journal of haematology.

[69]  S. Ghosh,et al.  NF-κB, the first quarter-century: remarkable progress and outstanding questions. , 2012, Genes & development.

[70]  Michael A. Freitas,et al.  Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL) , 2012, Proceedings of the National Academy of Sciences.

[71]  H. Glimm,et al.  Can Prognostic Factors Be Used to Direct Therapy in Chronic Lymphocytic Leukemia? , 2012, Current Hematologic Malignancy Reports.

[72]  Y. Pekarsky,et al.  Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. , 2012, Blood.

[73]  R. Foà,et al.  ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression , 2012, Haematologica.

[74]  L. Pasqualucci,et al.  Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. , 2011, Blood.

[75]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[76]  J. Burger.  Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. , 2011, Hematology. American Society of Hematology. Education Program.

[77]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[78]  L. Pasqualucci,et al.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.

[79]  K. Do,et al.  Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  F. Bosch,et al.  ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. , 2011, Blood.

[81]  G. Packham,et al.  B-cell receptor signaling in chronic lymphocytic leukemia. , 2011, Blood.

[82]  Wentian Li,et al.  Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells , 2011, Molecular medicine.

[83]  K. Keyvanfar,et al.  Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1 , 2011, Leukemia & lymphoma.

[84]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[85]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[86]  Jeffrey A Jones,et al.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.

[87]  M. Dyer,et al.  CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. , 2011, Leukemia research.

[88]  R. Oostendorp,et al.  Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1 , 2011, Leukemia.

[89]  Kenneth C. Anderson,et al.  Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.

[90]  M. Strout,et al.  Chronic lymphocytic leukemia: prognostic factors and impact on treatment. , 2011, Discovery medicine.

[91]  J. Friedberg.  CLL microenvironment: macro important. , 2011, Blood.

[92]  G. Marti,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[93]  Lei Guo,et al.  Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. , 2011, Blood.

[94]  Jeffrey A Jones,et al.  Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia , 2010 .

[95]  I. Screpanti,et al.  NOTCH1 PEST domain mutation is an adverse prognostic factor in B‐CLL , 2010, British journal of haematology.

[96]  H. Döhner,et al.  TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  G. Mufti,et al.  Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. , 2010, Cancer research.

[98]  T. Gornet,et al.  High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. , 2010, American journal of clinical pathology.

[99]  V. Gandhi,et al.  Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. , 2010, Blood.

[100]  D. Rossi,et al.  CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells , 2010, Leukemia.

[101]  S. Deaglio,et al.  CD38/CD31 Interactions Activate Genetic Pathways Leading to Proliferation and Migration in Chronic Lymphocytic Leukemia Cells , 2010, Molecular medicine.

[102]  D. Colomer,et al.  NF-κB as a therapeutic target in chronic lymphocytic leukemia , 2010, Expert opinion on therapeutic targets.

[103]  Marie Sevov,et al.  IGHV3‐21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia , 2010, European journal of haematology.

[104]  C. Croce,et al.  miR-15a and miR-16-1 in cancer: discovery, function and future perspectives , 2010, Cell Death and Differentiation.

[105]  A. Pettitt,et al.  Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia , 2010, Leukemia.

[106]  A. Califano,et al.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. , 2010, Cancer cell.

[107]  J. Gribben.  How I treat CLL up front. , 2010, Blood.

[108]  M. Nicoloso,et al.  Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features , 2010, Clinical Cancer Research.

[109]  E. Campo,et al.  Common variants at 2q37.3, 8q24.21, 15q21.3, and 16q24.1 influence chronic lymphocytic leukemia risk , 2010, Nature Genetics.

[110]  Š. Pospíšilová,et al.  Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.

[111]  N. Chiorazzi,et al.  In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. , 2009, Blood.

[112]  M. Hallek,et al.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. , 2009, Blood.

[113]  Z. Estrov,et al.  Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. , 2009, Blood.

[114]  C. Fegan,et al.  NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. , 2009, Future oncology.

[115]  I. Screpanti,et al.  A new genetic lesion in B‐CLL: a NOTCH1 PEST domain mutation , 2009, British journal of haematology.

[116]  M. Keating,et al.  B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. , 2009, Blood.

[117]  T. Cotter,et al.  Apoptosis and cancer: the genesis of a research field , 2009, Nature Reviews Cancer.

[118]  S. Deaglio,et al.  Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation , 2009, Haematologica.

[119]  D. Rossi,et al.  CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. , 2009, Cancer research.

[120]  P. Secchiero,et al.  Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. , 2009, Blood.

[121]  K. Do,et al.  Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  M. Karin,et al.  Regulation and function of NF-kappaB transcription factors in the immune system. , 2009, Annual review of immunology.

[123]  C. Fegan,et al.  Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  E. Kimby,et al.  TCL1A expression delineates biological and clinical variability in B-cell lymphoma , 2009, Modern Pathology.

[125]  I. Screpanti,et al.  Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. , 2009, Blood.

[126]  M. Grever,et al.  Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. , 2009, Blood.

[127]  Susan Slager,et al.  Validation of a new prognostic index for patients with chronic lymphocytic leukemia , 2009, Cancer.

[128]  B. Cheson,et al.  Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. , 2009, Blood.

[129]  C. Fegan,et al.  The Novel Nuclear Factor-κB Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine , 2008, Clinical Cancer Research.

[130]  F. Bosch,et al.  Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. , 2008, Cancer research.

[131]  K. Stamatopoulos,et al.  Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation , 2008, Journal of internal medicine.

[132]  Derek A. West,et al.  17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. , 2008, Blood.

[133]  Lisa S. Chen,et al.  Mcl-1: the 1 in CLL. , 2008, Blood.

[134]  T. Stankovic,et al.  Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. , 2008, Blood.

[135]  L. Vassilev,et al.  p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. , 2008, Blood.

[136]  Axel Benner,et al.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.

[137]  D. Rossi,et al.  CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia , 2008, Haematologica.

[138]  Sonia Jain,et al.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. , 2008, Blood.

[139]  S. Chiaretti,et al.  BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. , 2008, Blood.

[140]  L. Lagneaux,et al.  Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients , 2008, Leukemia.

[141]  C. Croce,et al.  Surface Expression of Bcl-2 in Chronic Lymphocytic Leukemia and Other B-Cell Leukemias and Lymphomas Without a Breakpoint t(14;18) , 2008, Molecular medicine.

[142]  J. Salisbury,et al.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. , 2008, Blood.

[143]  C. Fegan,et al.  The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. , 2008, Blood.

[144]  S. Deaglio,et al.  CD38 at the junction between prognostic marker and therapeutic target. , 2008, Trends in molecular medicine.

[145]  C. Croce,et al.  MiR-15a and miR-16-1 cluster functions in human leukemia , 2008, Proceedings of the National Academy of Sciences.

[146]  L. Rassenti,et al.  ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. , 2008, Blood.

[147]  T. Shanafelt,et al.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential , 2008, British journal of haematology.

[148]  Luca Laurenti,et al.  The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. , 2008, Blood.

[149]  F. Buccisano,et al.  Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. , 2008, Blood.

[150]  S. Deaglio,et al.  CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. , 2007, Blood.

[151]  R. Siebert,et al.  Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  Jian-yong Li,et al.  [Prognostic significance of lactate dehydrogenase and beta2-microglobulin in chronic lymphocytic leukemia]. , 2007, Zhongguo shi yan xue ye xue za zhi.

[153]  N. Chiorazzi,et al.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. , 2007, Blood.

[154]  Tapas K Sengupta,et al.  Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. , 2007, Blood.

[155]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[156]  Gabriel Pons,et al.  Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. , 2006, Experimental hematology.

[157]  T. Gilmore.  Introduction to NF-κB: players, pathways, perspectives , 2006, Oncogene.

[158]  Lisa L. Smith,et al.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. , 2006, Blood.

[159]  S. Deaglio,et al.  In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. , 2006, Blood.

[160]  R. Houlston,et al.  Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. , 2006, Blood.

[161]  R. Fanin,et al.  Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). , 2006, Blood.

[162]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[163]  A. Utsunomiya,et al.  DHMEQ, a new NF-κB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells , 2006, Leukemia.

[164]  S. Richardson,et al.  ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). , 2006, Blood.

[165]  A. Toker,et al.  Akt signaling and cancer: surviving but not moving on. , 2006, Cancer research.

[166]  L. Medeiros,et al.  TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state , 2006, Leukemia.

[167]  B. Saka,et al.  Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia. , 2006, Clinical and laboratory haematology.

[168]  S. Molica.  Sex differences in incidence and outcome of chronic lymphocytic leukemia patients , 2006, Leukemia & lymphoma.

[169]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[170]  T. Kipps,et al.  ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. , 2005, Blood.

[171]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[172]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[173]  Hirokazu Tamamura,et al.  Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. , 2005, Blood.

[174]  T. Kipps,et al.  Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. , 2005, Blood.

[175]  P. Jeggo,et al.  Harmonising the response to DSBs: a new string in the ATM bow. , 2005, DNA repair.

[176]  D. Spiller,et al.  CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. , 2005, Blood.

[177]  David P Lane,et al.  A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. , 2005, Blood.

[178]  S. Deaglio,et al.  CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. , 2005, Blood.

[179]  M. Prevost,et al.  Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains. , 2005, Blood.

[180]  L. Rassenti,et al.  ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. , 2005, Blood.

[181]  P. Chiusolo,et al.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. , 2004, Blood.

[182]  M. Cheang,et al.  Role of Myeloid Cell Factor-1 (Mcl-1) in Chronic Lymphocytic Leukemia , 2004, Leukemia & lymphoma.

[183]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[184]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[185]  F. Stevenson,et al.  Chronic lymphocytic leukemia: revelations from the B-cell receptor. , 2004, Blood.

[186]  Lisa L. Smith,et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.

[187]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[188]  I. Ghobrial,et al.  Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. , 2004, Mayo Clinic proceedings.

[189]  R. Rosenquist,et al.  VH3-21 Gene Usage in Chronic Lymphocytic Leukemia – Characterization of a New Subgroup with Distinct Molecular Features and Poor Survival , 2004, Leukemia & lymphoma.

[190]  P. Tandon,et al.  Mcl‐1 and Bcl‐2/Bax ratio are associated with treatment response but not with Rai stage in B‐cell chronic lymphocytic leukemia , 2004, American journal of hematology.

[191]  J. Reed,et al.  Microenvironmental Interactions and Survival of CLL B-cells , 2004, Leukemia & lymphoma.

[192]  T. Möröy,et al.  ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia , 2003, Leukemia.

[193]  S. Deaglio,et al.  CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. , 2003, Blood.

[194]  Adrian Wiestner,et al.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.

[195]  J. Barretina,et al.  CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease , 2003, Annals of Hematology.

[196]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[197]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[198]  A. Zanella,et al.  Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia. , 2003, Experimental hematology.

[199]  P. Circosta,et al.  CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. , 2003, Blood.

[200]  Arthur Weiss,et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.

[201]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[202]  T. Kipps,et al.  Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. , 2002, Blood.

[203]  S. Cory,et al.  The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.

[204]  Neil E Caporaso,et al.  CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. , 2002, Blood.

[205]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[206]  J. Cawley,et al.  The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. , 2002, Blood.

[207]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[208]  J. Moyano,et al.  Engagement of α4β1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine , 2002, Journal of Leukocyte Biology.

[209]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[210]  Ash A. Alizadeh,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[211]  E. Cesarman,et al.  Survival of leukemic B cells promoted by engagement of the antigen receptor. , 2001, Blood.

[212]  Y. Pekarsky,et al.  Molecular basis of mature T-cell leukemia. , 2001, JAMA.

[213]  A. Pettitt,et al.  p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.

[214]  K. Do,et al.  CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[215]  M Chilosi,et al.  Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.

[216]  R. Rosenquist,et al.  CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. , 2001, Blood.

[217]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[218]  N Tsukada,et al.  Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.

[219]  J. Laine,et al.  The protooncogene TCL1 is an Akt kinase coactivator. , 2000, Molecular cell.

[220]  D. Campana,et al.  CD38 in hematopoiesis. , 2000, Chemical immunology.

[221]  C D Baroni,et al.  Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. , 2000, Cancer research.

[222]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[223]  E. Schattner,et al.  Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells1 , 2000, The Journal of Immunology.

[224]  R. Greil,et al.  Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. , 2000, American journal of clinical pathology.

[225]  F. Cotter,et al.  Antisense‐mediated suppression of Bcl‐2 highlights its pivotal role in failed apoptosis in B‐cell chronic lymphocytic leukaemia , 1999, British journal of haematology.

[226]  L. Kanz,et al.  Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1) , 1999, Leukemia.

[227]  T. Kipps,et al.  Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. , 1999, Blood.

[228]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[229]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[230]  C. Denny,et al.  TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[231]  H. Döhner,et al.  Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.

[232]  Y. Pekarsky,et al.  Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[233]  E. Thiel,et al.  Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.

[234]  S. Molica,et al.  Clinico‐prognostic implications of simultaneous increased serum levels of soluble CD23 and β2‐microglobulin in B‐cell chronic lymphocytic leukemia , 1999, European journal of haematology.

[235]  A. García-Pardo,et al.  Fibronectin interaction with α4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax , 1999, Leukemia.

[236]  P. Tassone,et al.  Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells , 1998 .

[237]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[238]  A. A. Thompson,et al.  Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. , 1997, Blood.

[239]  M. James,et al.  11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. , 1997, Blood.

[240]  C. Pepper,et al.  REGULATION OF CLINICAL CHEMORESISTANCE BY bcl‐2 AND BAX ONCOPROTEINS IN B‐CELL CHRONIC LYMPHOCYTIC LEUKAEMIA , 1996, British journal of haematology.

[241]  S. Chevret,et al.  Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. , 1996, Blood.

[242]  A. Taylor,et al.  Leukemia and lymphoma in ataxia telangiectasia. , 1996, Blood.

[243]  E. Montserrat,et al.  Chronic lymphocytic leukemia. , 1995, The New England journal of medicine.

[244]  T. Kurosaki,et al.  Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase. , 1995, Immunity.

[245]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[246]  K.,et al.  Ligation of CD38 suppresses human B lymphopoiesis , 1995, The Journal of experimental medicine.

[247]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[248]  C. Gasche,et al.  Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[249]  M. Dyer,et al.  BCL2 translocations in leukemias of mature B cells. , 1994, Blood.

[250]  S. Zupo,et al.  CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells , 1994, European journal of immunology.

[251]  E. Newcomb,et al.  p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .

[252]  John Calvin Reed,et al.  bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .

[253]  Weiss Ns.  Geographical variation in the incidence of the leukemias and lymphomas. , 1979 .

[254]  A. Kohlmann,et al.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients , 2014, Leukemia.

[255]  S. Deaglio,et al.  Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. , 2013, Cancer letters.

[256]  L. Pasqualucci,et al.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. , 2013, Blood.

[257]  Luca Laurenti,et al.  Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. , 2012, Blood.

[258]  M. Hallek,et al.  Prognostic factors in chronic lymphocytic leukemia—what do we need to know? , 2011, Nature Reviews Clinical Oncology.

[259]  H. Döhner,et al.  From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.

[260]  V. Gandhi,et al.  AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. , 2009, Blood.

[261]  J. Philippé,et al.  Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. , 2009, Blood reviews.

[262]  B. Abbott.  Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. , 2006, The oncologist.

[263]  E. Montserrat,et al.  Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. , 2005, Haematologica.

[264]  G. Dighiero.  CLL biology and prognosis. , 2005, Hematology. American Society of Hematology. Education Program.

[265]  R. Porcher,et al.  Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL , 2003, Leukemia.

[266]  J. Dürig,et al.  CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia , 2002, Leukemia.

[267]  P. Biggs,et al.  Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. , 2002, Blood.

[268]  D. Cantrell,et al.  T cell activation and the cytoskeleton. , 2000, Annual review of immunology.

[269]  Peter Lichter,et al.  Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis , 1999, Journal of Molecular Medicine.

[270]  Xianglin Shi,et al.  New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. , 1999, Clinical chemistry.

[271]  P. Giallonardo,et al.  Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. , 1989, Acta haematologica.